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Hereditary lymphedema is a developmental disorder characterized by chronic swelling of the extremities due to
dysfunction of the lymphatic vessels. Two responsible genes have been identified: the vascular endothelial growth
factor receptor 3 (VEGFR3) gene, implicated in congenital lymphedema, or Milroy disease, and the forkhead-
related transcription factor gene FOXC2, causing lymphedema-distichiasis. We describe three families with an
unusual association of hypotrichosis, lymphedema, and telangiectasia. Usingmicrosatellite analysis, we first excluded
both VEGFR3 and FOXC2 as causative genes; we then considered the murine ragged phenotype, caused by
mutations in the Sox18 transcription factor, as a likely counterpart to the human disease, because it presents a
combination of hair and cardiovascular anomalies, including symptoms of lymphatic dysfunction. Two of the
families were consanguineous; in affected members of these families, we identified homozygous missense mutations
in the SOX18 gene, located in 20q13. The two amino acid substitutions, W95R and A104P, affect conserved
residues in the first a helix of the DNA-binding domain of the transcription factor. In the third family, the parents
were nonconsanguineous, and both the affected child and his brother, who died in utero with hydrops fetalis,
showed a heterozygous nonsense mutation that truncates the SOX18 protein in its transactivation domain; this
substitution was not found in genomic DNA from either parent and hence constitutes a de novo germline mutation.
Thus, we show that SOX18 mutations in humans cause both recessive and dominant hypotrichosis-lymphedema-
telangiectasia, suggesting that, in addition to its established role in hair and blood vessel development, the SOX18
transcription factor plays a role in the development and/or maintenance of lymphatic vessels.
Introduction
Lymphedema, a chronic swelling of the extremities that
is due to impaired lymphatic drainage, causes cosmet-
ic harm, disability, and predisposition to infection and
chronic ulceration. Primary lymphedema can be non-
inherited or hereditary, and, recently, progress has been
made in understanding the molecular bases of he-
reditary forms. Congenital hereditary lymphedema, or
Milroy disease (MIM 153100), has been found to be
caused by missense inactivating mutations in the ki-
nase domain of vascular endothelial growth factor re-
ceptor 3 (VEGFR3) (Irrthum et al. 2000; Karkkainen
et al. 2000), and lymphedema associated with disti-
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chiasis (MIM 153400), an additional row of eyelash-
es originating from the meibomian glands, has been
shown to be caused by truncating mutations in the
forkhead-related transcription factor FOXC2 (Fang et
al. 2000; Finegold et al. 2001). Lymphedema is also
observed in a few genetic syndromes—such as lymph-
edema-cholestasis (MIM 214900), or Aagenaes syn-
drome, mapped to chromosome 15q (Bull et al. 2000),
and lymphedema-microcephaly-chorioretinopathy
(MIM 152950) (Feingold and Bartoshesky 1992). Final-
ly, nuchal lymphedema and hydrops fetalis are frequent-
ly observed in patients with Noonan syndrome (MIM
163950) (Witt et al. 1987) and in patients with a variety
of chromosomal abnormalities, including Turner syn-
drome (Chitayat et al. 1989; Boucher et al. 2001).
The interest in the identification of genes involved
in hereditary lymphedema extends beyond the mere
understanding of this disorder. Conditions associat-
ed with lymphedema, such as Noonan syndrome, may
have higher incidences of lymphoproliferative disor-
ders (Choong et al. 1999). In addition, lymphangio-
genesis, the development of lymphatic vessels, has re-
cently been linked to tumor growth and metastasis, and
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Table 1
Summary of Clinical Findings in Patients with SOX18 Mutations
FAMILY I
FAMILY II
GIRL
FAMILY III
Boy Girl Boy Fetus
Hypotrichosis:
Scalp Very sparse Very sparse Sparse Very sparse …
Eyebrows Absent Absent Absent Absent …
Eyelashes Absent Absent Absent Absent …
Onset Age 0–6 mo Age 0–2 years Birth Age 6 mo …
Lymphedema:
Localization Legs Legs Legs Upper eyelid Generalized
Onset Age 15 years Puberty Age 4 years Birth Prenatal
Telangiectasia Not observed Palm of right hand Palms and soles Scalp, scrotum, and legs …
Other findings Thin and transparent skin
on hands and feet, bilateral
hydrocele
Thin and transparent skin
on hands and feet
Cutis marmorata–like lividity
of the skin, small dark-red
papular lesions on several toes
Mild eczema on cheeks,
scrotal edema, large
hydroceles
Nonimmune hydrops fetalis
Mode of inheritance Recessive Recessive Recessive Dominant Dominant
SOX18 mutation G455CrA104P (homozygous) G455CrA104P (homozygous) T428ArW95R (homozygous) C865ArC240X (heterozygous) C865ArC240X (heterozygous)
lymphedema genes are prime candidates as regulators
of this process. In particular, the VEGFR3 gene, impli-
cated in hereditary congenital lymphedema, has attract-
ed much attention as a promising anticancer-drug target
(Plate 2001). Overexpression of the VEGFR3 natural
ligands VEGFC and VEGFD has been shown to lead to
an increase in tumor growth and metastasis via the lym-
phatic system (Skobe et al. 2001; Stacker et al. 2001),
whereas a block of VEGFR3 signaling has been shown
to counteract these effects in the mouse (He et al. 2002).
Furthermore, the identification of genes causing hered-
itary lymphedema could lead to therapeutic advances
in the management of secondary lymphedema, such as
lymphedema resulting from anticancer surgery or par-
asitic disease.
We describe three families with an unusual hereditary
condition in which hypotrichosis, lymphedema, and tel-
angiectasia are associated. After excluding VEGFR3 and
FOXC2 as potential disease-causing genes, we identified
the murine ragged phenotype as a putative counterpart
of the human disorder. We found that SOX18, the human
orthologue of the ragged gene, is mutated in these three
families and accounts for both a recessive form and a
dominant form of the disease.
Subjects and Methods
Subjects
Clinical findings in all patients are summarized in
table 1. Written informed consent was obtained from
all participants, and the present study was approved
by the ethical committee of the medical faculty at the
Universite´ catholique de Louvain, Brussels, Belgium.
Family I.—The index patient is a boy, the first child
born to unaffected parents who are first cousins of Bel-
gian descent (Devriendt et al. 2002). He was born at 32
wk gestation, with birth weight of 1.650 kg (25th–50th
percentile), and presented with respiratory distress. A
normal amount of scalp hair was present at birth but
decreased progressively to the extent of total alopecia at
age 6 mo. Some hair growth was noted later (at age 3.5
years), but it remained very sparse (figs. 1A and 1B),
with absent eyebrows and eyelashes. Sweating, nails, and
teeth were normal. The skin over the hands and feet was
thin and transparent, with visible blood vessels. A skin
biopsy revealed several abortive hair follicles, some atro-
phic sebaceous glands, and normal sweat glands. A bilat-
eral hydrocele was surgically corrected at age 12 years.
At age ∼15 years, the patient progressively developed
lymphedema of the lower limbs. A Doppler ultrasono-
graphy of the venous system of the lower limbs done at
age 25 years was normal. A lymphatic scintigraphy was
performed by interdigital subcutaneous injection of a
radio-labeled (Technetium 99m) colloidal tracer into the
dorsal part of the foot. No tracer was detected in the
groin during a monitoring period of 32.5 min, indicating
that there was no detectable lymphatic flow.
His younger sister presented a similar phenotype. She
was born at 36 wk gestation with birth weight 2.7 kg
(50th percentile). Initially, she had normal black hair. A
vascular nevus was present on the palm of the right hand
and faded during childhood. During infancy, her hair di-
minished progressively, and, around age 2 years, her hair
was very sparse and has remained so ever since. She had
neither eyebrows nor eyelashes, and she did not develop
axillary or pubic hair at puberty. Around puberty, she
developed progressive lymphedema of the lower limbs
(fig. 1C). Doppler study of the venous system of the legs
was normal. Clinical examination at age 26 years showed,
besides the hair abnormalities, normal teeth and nails.
Sweating was normal, but her skin was thin. The skin
over her hands and feet was transparent, and dilated veins
and varicosities were apparent on the palm of her right
hand (fig. 1D). The pedigree of family I is shown in figures
2A and 3B.
Family II.—The index patient has been described in
detail elsewhere (Glade et al. 2001). In summary, she
is a 12-year-old child of unaffected, first-cousin, Turk-
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Figure 1 Physical features observed in patients. A and B, Male patient from family I at age 3.5 years. Note the sparse scalp hair and
absence of eyebrows. C, Lymphedema of the legs in the female patient from family I, at age 26 years. D, Telangiectasias on the palm in the
same patient (also at age 26 years). E, Male patient from family III. Note the sparse scalp hair and absence of eyebrows. F, Scrotal telangiectasias
in the same patient.
ish parents. Her younger brother is unaffected. Lymph-
edema appeared in the lower limbs at age 4 years. Scalp
hair has always been sparse, but with a normal ap-
pearance. Eyebrows and eyelashes were missing. Palms
and soles showed multiple telangiectasias, with ectatic
capillaries and cutis marmorata–like lividity of the skin.
Small dark-red papular vascular lesions were seen on
several toes. Her nails and teeth were normal. The ped-
igree of family II is shown in figure 3D. DNA from the
parents was not available.
Family III.—The index patient is a boy, born in 1997,
with sparse hair. He presented swelling of the upper eye-
lids, scrotal edema, and very large bilateral hydroceles.
Hair loss began at age ∼6 mo, accompanied by a lighten-
ing of its color. Now, at age ∼6 years, alopecia is almost
complete (fig. 1E), including eyebrows and eyelashes.
The patient presented mild eczema on the cheeks and
telangiectasias on the scalp, scrotum (fig. 1F), and legs.
His nails and teeth were normal.
The brother of the index patient died in utero at 30
wk gestation. The fetus had nonimmune hydrops fetalis,
with chylous effusions in the pleural and peritoneal cav-
ities. The lungs presented generalized vascular congestion
and a mild dilatation of lymphatic vessels. Parental phys-
ical examination showed no abnormalities. The pedigree
of family III is shown in figure 3F.
Microsatellite Analysis
Peripheral blood was obtained from participating
family members. For the deceased fetus of family III,
a tissue sample was used. DNA was extracted using
standard laboratory procedures. Microsatellite mark-
ers around the VEGFR3, FOXC2, and SOX18 genes
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Figure 2 Exclusion of VEGFR3 and FOXC2 as the gene for hy-
potrichosis-lymphedema-telangiectasia in family I. A, Pedigree of the
family. The two affected individuals are represented by blackened sym-
bols, and the index patient is indicated by an arrowhead. Note the
consanguinity in the family. B, Microsatellite markers surrounding
VEGFR3 and FOXC2. Intermarker physical distances (in kbp), marked
on the right, are based on the Human Genome Project sequence draft
assembly (UCSC Genome Bioinformatics), as of July 2002.
were identified on the basis of Entrez Map View (Na-
tional Center for Biotechnology Information), build
28, and the Unified Database (UDB) (Weizmann In-
stitute of Science [WIS] Bioinformatics and Biological
Computing), both as of January 2002. In addition, we
used an intronic CA-repeat microsatellite (VEGFR3-
CA in fig. 2B) in the VEGFR3 gene (Iljin et al. 2001).
Genotyping, using 32P-labeled oligonucleotides, was
performed as described elsewhere (Boon et al. 1999).
To rule out nonpaternity in family III, in which a de
novo mutation was observed, we genotyped the four
members of the family for 10 Weber set 8 microsatel-
lites from various chromosomes.
Database Search for Candidate Genes
for Hypotrichosis-Lymphedema-Telangiectasia
We searched for potential murine models for the
disease in the Jackson Laboratory Mouse Genome In-
formatics databases, using various available query
forms and the keywords “lymphedema,” “lymphatic,”
“chylous,” “chylothorax,” “edema,” “edematous,” and
“swelling.” Mouse phenotypes retrieved were evaluated
for their resemblance to the human condition.
SOX18 Gene Sequencing and Restriction-Enzyme
Analyses of Mutations
SOX18 gene structure was obtained from the Univer-
sity of California–Santa Cruz (UCSC) Genome Bioin-
formatics Web site (Human Genome Project Working
Draft, December 2001 freeze). A 1,550-bp PCR frag-
ment containing the full SOX18 coding sequence and
the 196-bp intervening intron was amplified using ge-
nomic DNA from patients and control individuals, was
purified using the Qiagen PCR purification columns
(Qiagen), and was sequenced on a CEQ2000 fluores-
cent capillary sequencer (Beckman Coulter). Sequenc-
es were further aligned and analyzed with Sequencher
3.1 (Gene Codes). The identified nucleotide substitu-
tions G455C, T428A, and C865A created additional
recognition sites for restriction enzymes MnlI, HphI,
and DdeI, respectively. The presence of these RFLPs
was tested in the members of the relevant family, as
well as in 96 control individuals from the genetical-
ly heterogeneous Belgian population. Oligonucleotide
sequences and reaction conditions for PCR amplifica-
tion, sequencing, and restriction analysis are available
from the authors on request.
Results
Exclusion of VEGFR3 and FOXC2—and Database
Identification of SOX18
In families I and II, the parents were first cousins and
presented no signs of either lymphatic or hair anomalies,
despite the marked phenotype of their children. This
strongly suggested an autosomal recessive mode of in-
heritance. To assess the possibility that the lymphedema-
causing genes VEGFR3 and FOXC2 are involved in the
syndrome, we determined the genotypes of the parents
of family I and their children for microsatellite markers
closely surrounding these genes (fig. 2B). The affected
siblings showed heterozygosity for markers at both loci,
excluding these genes as causative for the disease under
a recessive inheritance model.
A search in mouse databases identified the ragged
phenotype, caused by mutations in the Sox18 gene,
as a putative murine counterpart of human hypotri-
chosis-lymphedema-telangiectasia. The order of mark-
ers around human SOX18 was inconsistent between
integrated (UDB [WIS Bioinformatics and Biological
Computing]) and sequence-based (UCSC Genome Bio-
informatics) maps of the human genome, both as of
January 2002, and genotyping revealed an intermin-
gling of uninformative, recombinant, and potentially
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Figure 3 Families with hypotrichosis-lymphedema-telangiectasia and mutations in SOX18. A, C, and E, Electropherograms from
affected members of families I, II, and III and unrelated controls, demonstrating mutations G455C, T428A, and C865A (in the protein,
A104P, W95R, and C240X, respectively). WT p wild type. B, D, and F, Family pedigrees (with the individual for whom sequence is shown
indicated by an arrowhead) and MnlI and DdeI restriction-fragment analysis (for families I and III). C p digested control; Up undigested
PCR product; W p water control.
linked markers (data not shown). This prompted us to
analyze SOX18 by direct sequencing in the patients
with hypotrichosis-lymphedema-telangiectasia.
Homozygous SOX18 Mutations in Patients
from Families I and II
Sequencing of the SOX18 gene in family I, presenting
consanguinity, revealed a G455C transversion in the cod-
ing sequence (GenBank accession number NM_018419)
(fig. 3A). This nucleotide substitution caused the replace-
ment of alanine at position 104 in the SOX18 protein
(GenBank accession number NP_060889) by a proline
(A104P). The mutation was present at homozygous state
in the two affected children and at heterozygous state in
the unaffected parents (fig. 3B), in accordance with a re-
cessive inheritance pattern in a consanguineous family.
In consanguineous family II, we identified a T428A
transversion in the coding sequence, resulting in the
replacement of tryptophan at position 95 in the protein
by an arginine (W95R). This mutation was present at
homozygous state in the affected patient (fig. 3C).
Neither mutation was observed in the genomic DNA
from 96 control individuals (data not shown).
Heterozygous SOX18 Mutation in Patients
from Family III
In family III, we identified a C865A transversion in
the coding sequence (fig. 3E), transforming the codon
for cysteine at position 240 of the protein (TGC) into
a premature stop codon (TGA). The mutation was de-
tected at heterozygous state in DNA extracted from the
blood of the patient and the tissue of the deceased fetus
and was not present in genomic DNA from the parents
(fig. 3F). This mutation, which truncates the transcrip-
tion factor in its transactivating domain, was not ob-
served in genomic DNA from 96 control individuals.
The genotypes of the four members of the family, for
10 microsatellite markers, were compatible with pater-
nity (data not shown).
Discussion
To identify the gene causing hypotrichosis-lymphedema-
telangiectasia in three families, we first investigated the
possible involvement of VEGFR3 and FOXC2, the two
genes associated with lymphedema in humans (Fang et
al. 2000; Irrthum et al. 2000; Karkkainen et al. 2000;
Finegold et al. 2001). FOXC2, in particular, could be
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Figure 4 Positions of SOX18 mutations in patients with hypotrichosis-lymphedema-telangiectasia. A, Multiple alignment of protein
sequences around mutated residues W95 and A104, including representative members of the different SOX protein subfamilies. * p Amino
acids conserved in all 20 known SOX proteins. B, Superimposition of SOX18-mutated amino acids over the nuclear-magnetic-resonance model
of the homologous HMG domain of SRY (Protein Data Bank PDB ID 1J46), with W95 shown in magenta and A104 shown in red. The structure
was drawn with DINO. Positions of disease-causing amino acid substitutions in SOX9, SOX10, and SRY (obtained from Swiss-Prot [entries
P48436, P56693, and Q05066, respectively]) are shown in yellow in panels A and B. C, Schematic representation of SOX18, showing positions
of the three mutations. Thin boxes represent 5′ and 3′ UTRs, and thick boxes represent translated sequences. Regions corresponding to the
DNA-binding domain and the transactivation domain are shown in pink and beige, respectively. Positions corresponding to murine ragged
mutations (single-nucleotide deletions) are indicated by red circles.
considered to be an interesting candidate, because it
causes lymphedema, with variable age at onset, asso-
ciated with distichiasis (the presence of an additional
row of eyelashes). A hair abnormality was also seen in
the three families described here, and lymphedema was
not always present at birth. However, we were able to
exclude the two genes in one of the consanguineous
families by using microsatellite analysis.
We then searched for an animal model of the disease
in public databases. The chy mouse has recently been
identified as an animal model for congenital hereditary
lymphedema. As do human patients, the chy mouse
has an inactivating mutation in the VEGFR3 tyrosine
kinase domain and exhibits leg edema due to hypo-
plastic lymphatic vessels (Karkkainen et al. 2001). An
anomaly frequently observed in the chy mouse is the
occurrence of chylous ascites, which may be caused by
dysfunction of intestinal lymphatic vessels. Similarly,
the murine ragged phenotype, caused by a mutation in
the gene encoding the transcription factor Sox18, pre-
sents chylous ascites, in addition to sparse fur (Pennisi et
al. 2000b). Thus, we considered SOX18 to be a remark-
able candidate for the human hypotrichosis-lymphede-
ma-telangiectasia syndrome.
In adults, the SOX18 gene is expressed in a broad
range of tissues, including brain, heart, skeletal mus-
cle, spleen, kidney, liver, and lung (Pennisi et al. 2000c;
Hosking et al. 2001). It belongs to the SOX (Sry-type
high-mobility group [HMG] box) gene family, en-
coding transcription factors required in diverse devel-
opmental processes, such as lens formation, sex and
neural determination, spermatogenesis, chondrogen-
esis, and cardiac development (Wegner 1999). These
transcription factors are highly similar to each other in
the HMG domain, a 79-amino-acid DNA-binding mo-
tif that specifically binds to the heptameric sequence
(A/T)(A/T)CAA(A/T)G (Wegner 1999). Three mem-
bers of the SOX family are already associated with
a human disease. Mutations in SRY cause sex reversal
and gonadal dysgenesis (Berta et al. 1990; Jager et
al. 1990), mutations in SOX9 cause campomelic dys-
plasia with autosomal sex reversal (Foster et al. 1994;
Wagner et al. 1994), and mutations in SOX10 cause
Waardenburg-Hirschsprung syndrome (Pingault et al.
1998).
We identified recessive SOX18 missense mutations in
affected individuals from two consanguineous families (I
and II) with hypotrichosis-lymphedema-telangiectasia.
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The first recessive mutation, A104P, affects an alanine
that is conserved in most members of the SOX family
(fig. 4A). Because SOX18 and SRY are homologous and
present high sequence similarity in their respective HMG
domains, we used the nuclear-magnetic-resonance model
of SRY (Werner et al. 1995) to visualize the positions of
the two recessive mutations (fig. 4B). The alanine at po-
sition 104 (shown in red in the model) is located in the
first a helix of the DNA-binding domain, and its replace-
ment by a proline, an amino acid that produces significant
bends in a helices, is very likely to affect the structure of
this domain. The second recessive mutation, W95R, sub-
stitutes a tryptophan residue (shown in magenta in fig.
4) that is conserved in all SOX proteins. The three-di-
mensional structure of SRY reveals that this tryptophan
belongs to a cluster of conserved aromatic and aliphatic
residues that maintain orientation of the three a helices
of the DNA-binding domain through their packing (Wer-
ner et al. 1995), and the mutation thus probably desta-
bilizes the domain.
The C240X SOX18 mutation in family III, located
in the vicinity of the murine ragged frameshift mutations
(fig. 4C), causes a most-likely-dominant form of the
syndrome, since the patient and the fetus are hetero-
zygous for the substitution and since sequencing of the
complete coding region and splice sites did not reveal
additional genetic alterations. Moreover, the nucleotide
substitution was not found in DNA extracted from the
blood of the parents, and nonpaternity was ruled out,
implying that this mutation arose de novo. This is sim-
ilar to the situation for the other SOX genes associated
with human disorders (i.e., SRY, SOX9, and SOX10),
in which usually-de-novo mutations are observed at the
heterozygous state (Berta et al. 1990; Jager et al. 1990;
Foster et al. 1994; Wagner et al. 1994; Pingault et al.
1998). Like the autosomal SOX9 and SOX10 genes,
which presumably exert their effect through haploin-
sufficiency (Foster et al. 1994; Wagner et al. 1994; Pin-
gault et al. 1998), the C240X mutation may result in
a null allele. In this case, the proteins with the recessive
mutations should retain some activity. However, a dom-
inant-negative effect cannot be ruled out, because the
resulting protein is truncated in its transactivation do-
main and, if still present, may bind the promoters of
target genes via its intact DNA-binding domain.
The first component of the syndrome, early-onset
hypotrichosis with absence of eyebrows and eyelash-
es, is present in all patients with SOX18 mutations.
During murine embryonic development, Sox18 is tran-
siently expressed in the mesenchyme underlying the
vibrissae and pelage hair follicles, and its role in hair
development has been demonstrated by its implication
in the murine ragged phenotype (Pennisi et al. 2000b).
Its two closest paralogues, Sox7 and Sox17, have been
postulated to carry overlapping functions (Pennisi et
al. 2000a). Human SOX7 and Xenopus Sox17 phys-
ically interact with b-catenin and interfere with Wnt/
b-catenin signaling (Zorn et al. 1999; Takash et al.
2001), a pathway essential for hair morphogenesis
(Gat et al. 1998). b-Catenin controls fate decision of
the skin stem cells toward epidermal or follicular ke-
ratinocyte differentiation (Huelsken et al. 2001), and
the observed hypotrichosis could be due to abnormal
interference with this process by Sox18. Intriguingly,
mice with conditional inactivation of b-catenin after
hair-follicle formation show complete loss of pelage
after the first hair cycle, a phenotype reminiscent of
the human patients with SOX18 mutations.
The second component of the syndrome, lymphede-
ma, presented differently in the three families. The age
at onset of the lower-limb lymphedema was highly var-
iable, ranging from 4 to 15 years. The affected boy
from family III currently has no lower-limb lymphede-
ma, but he presented with edema of the upper eyelids.
A more severe failure of the lymphatic system present-
ed in his late brother, who had nonimmune hydrops
fetalis. This severe presentation was also observed in
two patients in a family with hereditary lymphedema-
distichiasis caused by a mutation in the FOXC2 gene
(Fang et al. 2000). The frequent involvement of the
lymphatic system among patients implies SOX18 in
development and/or maintenance of lymphatic vessels.
Because SOX proteins constitute a family of20 mem-
bers in humans (Schepers et al. 2002), have overlap-
ping expression patterns, and bind to the same DNA
heptamer motif, they are supposed to achieve specific-
ity through combinatorial associations with other fac-
tors (Wilson and Koopman 2002). Interaction with,
for example, FOXC2 or the lymphatic vessel regulator
PROX1 (Wigle and Oliver 1999) might enable SOX18
to specifically activate lymphatic-related target genes.
Such candidate targets are the genes encoding vascular
endothelial growth factors VEGFC and VEGFD, as well
as their receptor, VEGFR3. Indeed, direct regulation of
the VEGFC and VEGFD genes might be possible, be-
cause they contain the heptameric binding site for SOX
proteins in their promoters, as revealed by examination
of current sequence databases (data not shown).
The third component of the syndrome is an anom-
aly of peripheral blood vessels, manifesting as telangi-
ectasia in three of the four patients. Involvement of
blood vessels is not surprising, since Sox18 mRNA is
transiently detected in endothelial cells during mouse
embryonic development and since the Sox18-mutated
ragged mouse exhibits conspicuous vascular anom-
alies, such as hematomas and dilation or rupture of
peripheral blood vessels (Pennisi et al. 2000b); how-
ever, no signs of comparable vascular abnormalities
were observed in the patients. The telangiectasias, as
well as the other observed anomalies—such as thinness
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and transparency of the skin, hydrocele, and small cu-
taneous papular vascular lesions—were observed only
in some patients. The phenotypic heterogeneity is rem-
iniscent of that seen in lymphedema-distichiasis (Fine-
gold et al. 2001) and could be explained by the pres-
ence of modifier genes. In fact, the influence of modifi-
er genes has been demonstrated in the Sox18-deficient
ragged mouse, in which the accumulation of chyle in
the peritoneum depends on the genetic background
(Wallace 1979). Thus, SOX18 mutations are expect-
ed to present as isolated alopecia in some patients—es-
pecially young children, before the onset of lymphede-
ma—and as nonimmune hydrops fetalis of unknown
etiology in others.
Note added in proof.—While the present article was
in press, the finding of SOX2 mutations in patients with
anophthalmia was reported by Fantes et al. (2003).
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